Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CPRXNASDAQ:CRNXNASDAQ:HCMNASDAQ:IMTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCPRXCatalyst Pharmaceuticals$22.81-1.8%$23.94$14.75▼$26.58$2.78B0.721.14 million shs1.47 million shsCRNXCrinetics Pharmaceuticals$30.50-1.1%$31.42$24.10▼$62.53$2.86B0.28845,032 shs480,466 shsHCMHUTCHMED$15.43-1.8%$14.62$11.51▼$21.50$2.69B0.5299,966 shs39,187 shsIMTXImmatics$5.85-4.7%$5.08$3.30▼$13.09$711.07M0.83660,643 shs589,394 shs10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCPRXCatalyst Pharmaceuticals0.00%-6.09%-7.58%-5.86%+52.37%CRNXCrinetics Pharmaceuticals0.00%-5.19%-2.77%-11.39%-31.14%HCMHUTCHMED0.00%-12.92%+16.28%+2.94%-13.36%IMTXImmatics0.00%-4.72%+8.33%+17.00%-53.50%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCPRXCatalyst Pharmaceuticals4.8902 of 5 stars3.62.00.03.93.83.33.1CRNXCrinetics Pharmaceuticals3.5236 of 5 stars3.50.00.03.72.72.50.0HCMHUTCHMED1.3464 of 5 stars2.02.00.00.02.00.01.9IMTXImmatics2.6804 of 5 stars3.63.00.00.03.31.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCPRXCatalyst Pharmaceuticals 3.25Buy$32.8343.94% UpsideCRNXCrinetics Pharmaceuticals 2.91Moderate Buy$74.56144.44% UpsideHCMHUTCHMED 2.00Hold$19.0023.14% UpsideIMTXImmatics 3.20Buy$14.67150.71% UpsideCurrent Analyst Ratings BreakdownLatest IMTX, HCM, CRNX, and CPRX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/5/2025CPRXCatalyst PharmaceuticalsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/28/2025IMTXImmaticsDeutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$10.005/13/2025HCMHUTCHMEDHSBCSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Hold4/1/2025IMTXImmaticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight3/25/2025CRNXCrinetics PharmaceuticalsStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$60.00(Data available from 6/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCPRXCatalyst Pharmaceuticals$491.73M5.66$2.45 per share9.32$6.10 per share3.74CRNXCrinetics Pharmaceuticals$1.04M2,745.88N/AN/A$14.29 per share2.13HCMHUTCHMED$630.20M4.27$0.29 per share53.72$4.43 per share3.48IMTXImmatics$168.65M4.22$0.24 per share23.94$5.12 per share1.14Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCPRXCatalyst Pharmaceuticals$163.89M$1.5714.5310.710.9336.91%42.45%36.59%8/6/2025 (Estimated)CRNXCrinetics Pharmaceuticals-$298.41M-$3.82N/AN/AN/AN/A-30.95%-28.12%8/6/2025 (Estimated)HCMHUTCHMED$37.73MN/A0.0010.57N/AN/AN/AN/A7/29/2025 (Estimated)IMTXImmatics$16.47M-$0.17N/AN/AN/A-14.73%-4.52%-3.34%8/12/2025 (Estimated)Latest IMTX, HCM, CRNX, and CPRX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025IMTXImmatics-$0.39-$0.35+$0.04-$0.35$14.92 million$20.12 million5/8/2025Q1 2025CRNXCrinetics Pharmaceuticals-$0.99-$1.04-$0.05-$1.04$0.10 million$0.36 million3/27/2025Q4 2024IMTXImmatics-$0.03$0.48+$0.51$0.48$16.16 million$15.67 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCPRXCatalyst PharmaceuticalsN/AN/AN/AN/AN/ACRNXCrinetics PharmaceuticalsN/AN/AN/AN/AN/AHCMHUTCHMEDN/AN/AN/AN/AN/AIMTXImmaticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCPRXCatalyst PharmaceuticalsN/A6.145.96CRNXCrinetics PharmaceuticalsN/A22.5322.53HCMHUTCHMED0.082.832.70IMTXImmaticsN/A10.2810.28Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCPRXCatalyst Pharmaceuticals79.22%CRNXCrinetics Pharmaceuticals98.51%HCMHUTCHMED8.82%IMTXImmatics64.41%Insider OwnershipCompanyInsider OwnershipCPRXCatalyst Pharmaceuticals10.40%CRNXCrinetics Pharmaceuticals4.60%HCMHUTCHMED3.60%IMTXImmatics3.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCPRXCatalyst Pharmaceuticals80121.97 million109.29 millionOptionableCRNXCrinetics Pharmaceuticals21093.63 million89.32 millionOptionableHCMHUTCHMED1,811174.32 million168.05 millionNot OptionableIMTXImmatics260121.55 million117.54 millionOptionableIMTX, HCM, CRNX, and CPRX HeadlinesRecent News About These CompaniesImmatics (NASDAQ:IMTX) Shares Down 3.8% - Here's WhyJune 18 at 5:15 PM | marketbeat.comImmatics N.V. Shareholders Approve Key Resolutions at June 2025 AGMJune 18 at 2:22 PM | tipranks.comImmatics (NASDAQ:IMTX) Shares Up 4.4% - Here's What HappenedJune 12, 2025 | marketbeat.comCantor Fitzgerald Weighs in on Immatics FY2026 EarningsJune 12, 2025 | americanbankingnews.comImmatics (NASDAQ:IMTX) Sees Unusually-High Trading Volume - Here's What HappenedJune 11, 2025 | marketbeat.comCantor Fitzgerald Forecasts Immatics FY2026 EarningsJune 10, 2025 | marketbeat.comImmatics (NASDAQ:IMTX) Shares Down 4.9% - Should You Sell?June 9, 2025 | marketbeat.comMillennium Management LLC Has $1.11 Million Holdings in Immatics (NASDAQ:IMTX)June 5, 2025 | marketbeat.comImmatics: Taking Off On A PRAME RocketshipJune 4, 2025 | seekingalpha.comDoes Immatics (IMTX) Have the Potential to Rally 174.54% as Wall Street Analysts Expect?June 3, 2025 | zacks.comImmatics rises on data from early stage cell therapy trialJune 2, 2025 | msn.comImmatics Presents Promising IMA203 Data at ASCO 2025June 2, 2025 | tipranks.comImmatics (IMTX) Shares Promising Data from IMA203 Melanoma Trials | IMTX Stock NewsJune 1, 2025 | gurufocus.comImmatics IMA203 PRAME Cell Therapy Data Presented at 2025 ASCO Annual Meeting Continues to ...May 31, 2025 | gurufocus.comImmatics IMA203 PRAME Cell Therapy Data Presented at 2025 ASCO Annual Meeting Continues to ...May 31, 2025 | gurufocus.comImmatics IMA203 PRAME Cell Therapy Data Presented at 2025 ASCO Annual Meeting Continues to ...May 31, 2025 | gurufocus.comImmatics N.V. Reports Promising Long-Term Efficacy and Safety Data from Phase 1b Trial of IMA203 PRAME Cell Therapy in Metastatic MelanomaMay 31, 2025 | quiverquant.comImmatics IMA203 PRAME Cell Therapy Data Presented at 2025 ASCO Annual Meeting Continues to Show Strong Anti-tumor Activity and Durability in Patients with Metastatic MelanomaMay 31, 2025 | globenewswire.comWellington Management Group LLP Grows Position in Immatics (NASDAQ:IMTX)May 30, 2025 | marketbeat.comImmatics (NASDAQ:IMTX) Trading Up 4.1% - Time to Buy?May 29, 2025 | marketbeat.comImmatics (NASDAQ:IMTX) Given Average Recommendation of "Buy" by BrokeragesMay 29, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeIMTX, HCM, CRNX, and CPRX Company DescriptionsCatalyst Pharmaceuticals NASDAQ:CPRX$22.81 -0.41 (-1.77%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$23.11 +0.30 (+1.32%) As of 06/18/2025 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.Crinetics Pharmaceuticals NASDAQ:CRNX$30.50 -0.35 (-1.13%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$30.51 +0.01 (+0.03%) As of 06/18/2025 07:09 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.HUTCHMED NASDAQ:HCM$15.43 -0.28 (-1.78%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$15.55 +0.12 (+0.77%) As of 06/18/2025 04:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The Other Ventures segment involves the other commercial businesses which include the sales, marketing, manufacture, and distribution of prescription drugs and healthcare products. The company was founded on December 18, 2000 and is headquartered in Hong Kong.Immatics NASDAQ:IMTX$5.85 -0.29 (-4.72%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$6.02 +0.18 (+2.99%) As of 06/18/2025 06:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes IMA203 that targets solid tumors, which is in Phase 1b clinical trial; IMA203CD8, a cell therapy product that is in Phase 1b clinical trial; IMA204 that targets tumor stroma, which is in preclinical stage; and IMA30x, an allogenic cellular therapy product candidate, which is in preclinical stage. The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Robinhood Director Sells Millions, But HOOD Stock Eyes Gains Coinbase Stock Pops as Senate Passes GENIUS Stablecoin Bill Chime’s Smart IPO: Half the Valuation, Double the Strength 3 Tech Stocks With High and Rising Institutional Interest Salesforce Raises Prices: 3 Reasons Its Stock Price Will Follow Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
